Samantha Pearce Biography and Net Worth

Samantha Pearce was appointed Jazz’s senior vice president of Europe and International in March 2020. With more than 30 years of experience in the pharmaceutical industry, Ms. Pearce has a track record of scaling commercial operations to achieve transformational growth and accelerated access to medicines across geographies. She is particularly passionate and effective at unifying teams around a singular vision and instilling a performance and enterprise mindset.

From March 2010 to December 2019, Ms. Pearce held various global senior management positions with Celgene Corporation, most recently as vice president and general manager of international markets. Prior to that, from August 2002 to March 2010, she served in management positions at AstraZeneca plc, culminating in her role as director of specialist care. Prior to August 2002, she worked for DuPont Pharmaceuticals. Ms. Pearce received a B.Sc. from Birmingham University, U.K. and an M.B.A. from Cranfield University, UK.

What is Samantha Pearce's net worth?: The estimated net worth of Samantha Pearce is at least $1.39 million as of January 3rd, 2023. Ms. Pearce owns 11,309 shares of Jazz Pharmaceuticals stock worth more than $1,390,668 as of December 21st. This net worth evaluation does not reflect any other investments that Ms. Pearce may own. Learn More about Samantha Pearce's net worth.
How old is Samantha Pearce?: Ms. Pearce is currently 58 years old. There are 7 older executives and no younger executives at Jazz Pharmaceuticals. The oldest executive at Jazz Pharmaceuticals is Mr. Bruce C. Cozadd, Co-Founder, Chairman & CEO, who is 60 years old. Learn More on Samantha Pearce's age.
How do I contact Samantha Pearce?: The corporate mailing address for Ms. Pearce and other Jazz Pharmaceuticals executives is FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD, DUBLIN L2, D04. Jazz Pharmaceuticals can also be reached via phone at (531) 634-7800 and via email at [email protected]. Learn More on Samantha Pearce's contact information.
Has Samantha Pearce been buying or selling shares of Jazz Pharmaceuticals?: Samantha Pearce has not been actively trading shares of Jazz Pharmaceuticals during the last quarter. Most recently, Samantha Pearce sold 531 shares of the business's stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $159.59, for a transaction totalling $84,742.29. Following the completion of the sale, the senior vice president now directly owns 11,309 shares of the company's stock, valued at $1,804,803.31. Learn More on Samantha Pearce's trading history.
Who are Jazz Pharmaceuticals' active insiders?: Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?: During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company. Learn More about insider trades at Jazz Pharmaceuticals.
Information on this page was last updated on 12/2/2024.

Samantha Pearce Insider Trading History at Jazz Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/3/2023	Sell	531	$159.59	$84,742.29	11,309
12/13/2022	Sell	531	$155.45	$82,543.95	11,309
11/10/2022	Sell	1,063	$155.00	$164,765.00	11,309
8/4/2022	Sell	531	$155.00	$82,305.00	11,309
7/12/2022	Sell	532	$155.00	$82,460.00	11,309
6/27/2022	Sell	8,508	$155.00	$1,318,740.00	11,309
6/8/2022	Sell	8,487	$155.00	$1,315,485.00	11,309

Samantha Pearce Buying and Selling Activity at Jazz Pharmaceuticals

Jazz Pharmaceuticals Company Overview

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Today's Range

Now: $122.97

$121.37

$124.39

50 Day Range

MA: $118.89

$108.05

$127.74

2 Week Range

Now: $122.97

$99.06

$134.17

Volume

1,767,343 shs

Average Volume

675,822 shs

Market Capitalization

$7.43 billion

P/E Ratio

17.32

Dividend Yield

N/A

Beta

0.57

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Samantha Pearce Biography and Net Worth

What is Samantha Pearce's net worth?

How old is Samantha Pearce?

How do I contact Samantha Pearce?

Has Samantha Pearce been buying or selling shares of Jazz Pharmaceuticals?

Who are Jazz Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Jazz Pharmaceuticals?